Abstract：
OBJECTIVE: Neuromuscular muscle relaxants are still indispensable for surgical procedures requiring general anesthesia, and the use of these agents may result in postoperative residual curarization. Sugammadex may offer a distinct advantage to pediatric patients where residual neuromuscular blockade may be poorly tolerated. Sugammadex is approved for use in adults and children over two years. This is the main reason why large-scale studies could not be conducted in the group of patients younger than two years old. This study aimed to evaluate the efficacy and safety of sugammadex for reversing deep rocuronium-induced neuromuscular blockade in children under two years of age.
METHODS: Pediatric patients younger than two years of age who underwent neurosurgery under sevoflurane anesthesia were included in the study. Neuromuscular block was achieved by the administration of rocuronium. It was antagonized by the administration of 5 mg/kg sugammadex and evaluated using train-of-four (TOF). Primary outcome measure was the time from sugammadex administration to return of the TOF ratio to 0,9. Postoperative adverse events were also recorded.
RESULTS: Two hundred eighty patients (10 day-24 months of age; 3-18 kg) were included in this study. Reversal of deep rocuronium-induced neuromuscular block with sugammadex was rapid in all patients. No residual curarization or recurarization was observed. No adverse events or hypersensitivity reactions were observed after administration of sugammadex. CONCLUSİON: Reversal of rocuronium-induced deep neuromuscular block in infants was rapid and safe. Sugammadex provided safe extubation in patients younger than two years of age who had undergone neurosurgery. Research Fund.
BACKGROUND: Neuromuscular blockade, Neuromuscular monitoring, Pediatrics, Sugammadex.
METHODS: Pediatric patients younger than two years of age who underwent neurosurgery under sevoflurane anesthesia were included in the study. Neuromuscular block was achieved by the administration of rocuronium. It was antagonized by the administration of 5 mg/kg sugammadex and evaluated using train-of-four (TOF). Primary outcome measure was the time from sugammadex administration to return of the TOF ratio to 0,9. Postoperative adverse events were also recorded.
RESULTS: Two hundred eighty patients (10 day-24 months of age; 3-18 kg) were included in this study. Reversal of deep rocuronium-induced neuromuscular block with sugammadex was rapid in all patients. No residual curarization or recurarization was observed. No adverse events or hypersensitivity reactions were observed after administration of sugammadex. CONCLUSİON: Reversal of rocuronium-induced deep neuromuscular block in infants was rapid and safe. Sugammadex provided safe extubation in patients younger than two years of age who had undergone neurosurgery. Research Fund.
BACKGROUND: Neuromuscular blockade, Neuromuscular monitoring, Pediatrics, Sugammadex.
摘要：
目的：神经肌肉松弛剂对于需要全身麻醉的外科手术仍然是不可缺少的，使用这些药物可能会导致术后残留的curarization。Sugammadex可能为残余神经肌肉阻滞可能耐受性较差的儿科患者提供了明显的优势。Sugammadex被批准用于成人和儿童超过两年。这是无法在两岁以下患者组中进行大规模研究的主要原因。本研究旨在评估Sugammadex逆转2岁以下儿童深罗库溴铵诱导的神经肌肉阻滞的疗效和安全性。
方法：在七氟醚麻醉下接受神经外科手术的2岁以下儿童患者被纳入研究。通过给予罗库溴铵实现神经肌肉阻滞。通过施用5mg/kg的sugammadex来拮抗它，并使用四组（TOF）进行评估。主要结果指标是从sugammadex给药到TOF比率恢复到0.9的时间。记录术后不良事件。
结果：本研究纳入了280名患者（10天至24个月大；3-18公斤）。在所有患者中，用Sugammadex逆转深罗库溴铵诱导的神经肌肉阻滞都很快。没有观察到残留的固化或递归。施用sugammadex后未观察到不良事件或超敏反应。结论：罗库溴铵诱导的婴儿深层神经肌肉阻滞逆转是快速和安全的。Sugammadex为接受神经外科手术的两岁以下患者提供了安全的拔管。研究基金。
背景：神经肌肉阻滞，神经肌肉监测,儿科,Sugammadex.
方法：在七氟醚麻醉下接受神经外科手术的2岁以下儿童患者被纳入研究。通过给予罗库溴铵实现神经肌肉阻滞。通过施用5mg/kg的sugammadex来拮抗它，并使用四组（TOF）进行评估。主要结果指标是从sugammadex给药到TOF比率恢复到0.9的时间。记录术后不良事件。
结果：本研究纳入了280名患者（10天至24个月大；3-18公斤）。在所有患者中，用Sugammadex逆转深罗库溴铵诱导的神经肌肉阻滞都很快。没有观察到残留的固化或递归。施用sugammadex后未观察到不良事件或超敏反应。结论：罗库溴铵诱导的婴儿深层神经肌肉阻滞逆转是快速和安全的。Sugammadex为接受神经外科手术的两岁以下患者提供了安全的拔管。研究基金。
背景：神经肌肉阻滞，神经肌肉监测,儿科,Sugammadex.
